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Antagonism of the dopamine D3 receptor has been hypothesized to be beneﬁcial for schizophrenia
cognitive deﬁcits, negative symptoms and extrapyramidal symptoms. However, recent animal and hu-
man studies have shown that most antipsychotics do not occupy D3 receptors in vivo, despite their
considerable binding afﬁnity for this receptor in vitro. In the present study, we investigated the D3 re-
ceptor binding of blonanserin, a dopamine D2/D3 and serotonin 5-HT2A receptors antagonist, in vitro and
in vivo. Blonanserin showed the most potent binding afﬁnity for human D3 receptors among the tested
atypical antipsychotics (risperidone, olanzapine and aripiprazole). Our GTPgS-binding assay demon-
strated that blonanserin acts as a potent full antagonist for human D3 receptors. All test-drugs exhibited
antipsychotic-like efﬁcacy in methamphetamine-induced hyperactivity in rats. Treatment with blo-
nanserin at its effective dose blocked the binding of [3H]-(þ)-PHNO, a D2/D3 receptor radiotracer, both in
the D2 receptor-rich region (striatum) and the D3 receptor-rich region (cerebellum lobes 9 and 10). On
the other hand, the occupancies of other test-drugs for D3 receptors were relatively low. In conclusion,
we have shown that blonanserin, but not other tested antipsychotics, extensively occupies D3 receptors
in vivo in rats.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Multiple lines of evidence suggest that antagonism of the
dopamine D2 receptor contributes to improvement of positive
symptoms, whereas blockade of serotonin 5-HT2A receptor is
associated with improvement of negative symptoms as well as low
risk of extrapyramidal side effects in schizophrenia (1,2). In addi-
tion to their action on these two key receptors, dopamine D3 re-
ceptor has increasingly been considered as an attractive
therapeutic target for schizophrenia (3,4). Indeed, recent animal
studies using selective dopamine D3 receptor antagonists or
dopamine D3 receptor-deﬁcient mice have shown that antagonism
of this receptor is associated with a number of beneﬁcial effects,
including improvement of cognitive dysfunction and negative
symptoms, and attenuation of extrapyramidal side effects (3e5).and 10; PET, positron emis-
: þ81 6 6337 5109.
(T. Enomoto).
acological Society.
Production and hosting by ElsevieMost typical and atypical antipsychotics possess considerable
binding afﬁnity for the D3 receptor in vitro (6,7). However, several
studies have shown that the antipsychotics haloperidol, aripipra-
zole, clozapine, olanzapine and risperidone exhibit no or very low
occupancy of the rat D3 receptor ex vivo or in vivo (6e9).
Furthermore, human positron emission tomography (PET) studies
have revealed that the antipsychotics clozapine, olanzapine and
risperidone do not occupy D3 receptors in the brain of patients with
schizophrenia (10,11). Based on these ﬁndings, it is believed that
antagonism of D3 receptors does not contribute to the clinical
efﬁcacy of these antipsychotics.
Blonanserin is an atypical antipsychotic that has high selectivity
for the dopamine D2/D3 and the serotonin 5-HT2A receptors over
other receptors (12). Unlike most other atypical antipsychotics (13),
the binding afﬁnity of blonanserin for D2 receptors (Ki ¼ 0.284 nM)
is slightly higher than that for 5-HT2A receptors (Ki ¼ 0.64 nM)
in vitro (12). However, several animal studies have shown that
blonanserin exhibits “atypical characteristics”, such as low risk of
catalepsy, improvement of cortical dopamine transmission, and
efﬁcacy in rodent models of negative symptoms and cognitive
deﬁcits in schizophrenia (14e18). Furthermore, a meta-analysis ofr B.V. All rights reserved.
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for negative symptoms with lower risk of akathisia than haloper-
idol in patients with schizophrenia (19).
Considering that antagonistic action of blonanserin on the D3
receptor might contribute, at least in part, to its efﬁcacy and
tolerability, we compared in this study dopamine D3 receptor
binding of blonanserin to that of other atypical antipsychotics both
in vitro and in vivo.
2. Materials and methods
2.1. Animals
Male SpragueeDawley rats (Japan SLC Inc., Shizuoka, Japan)
and RccHan™: WIST rats (Japan Laboratory Animals, Inc., Tokyo,
Japan) were used for behavioral and binding experiments,
respectively. All animals were housed in a controlled environment
with a 12/12 h light/dark cycle. The animals had free access to food
and water. All procedures involving the use of animals were
reviewed and approved by the Institutional Animal Care and Use
Committee of Sumitomo Dainippon Pharma Co., Ltd. (Osaka,
Japan) or Shin Nippon Biomedical Laboratories, Ltd. (Wakayama,
Japan).
2.2. Drugs
Blonanserin, aripiprazole, olanzapine and risperidone were
synthesized in Sumitomo Dainippon Pharma Co., Ltd or purchased
from Wako Pure Chemical Industries (Osaka, Japan). SB-277011-A
hydrochloride hydrate and [3H](þ)-PHNO (30e60 Ci/mmol) were
purchased from SigmaeAldrich (St. Louis, Mo, USA) and Moravek
Biochemical (Brea, CA, USA), respectively. All tested drugs were
suspended in 0.5% tragacanth or 0.5% methylcellulose, and [3H]-
PHNO was dissolved in saline (0.15 nmol/0.289 MBq/mL). All drug
doses were expressed in terms of the free base. Doses of all anti-
psychotics used in in vivo dopamine D2/D3 receptors occupancy
were based on the effective dose of each drug in the rat
methamphetamine-induced locomotor hyperactivity model. A
tracer dose of [3H]-(þ)-PHNO (0.3 nmol/kg i.v.) was based on the
dose used in a previous paper (9).
2.3. In vitro binding assay
The in vitro binding assay was performed on our behalf by
Sekisui Medical Co., Ltd (Ibaraki, Japan) using the standard protocol
(12). In the presence or absence of test compounds, the membrane
preparations from Chinese hamster ovary K1 cells expressing hu-
man dopamine D3 receptors were incubated with 1.05e1.07 nM
[3H]-spiperone for 60 min at 25 C (PerkinElmer, Inc., Waltham,
USA). Nonspeciﬁc binding was estimated in the presence of 10 mM
(þ)-Butaclamol hydrochloride (SigmaeAldrich). The IC50 value,
which refers to inhibition of ligand speciﬁc binding by 50%, was
calculated for each test-drug. Test-drugs Ki values were calculated
using the following equation: Ki ¼ IC50/(1 þ L/Kd), where L is the
radioligand concentration used in the assay and Kd is its dissocia-
tion constant.
2.4. In vitro GTPgS binding assay
The in vitro GTPgS binding assay for human D2L and D3 re-
ceptors which stably expressed in the membranes of recombinant
Chinese hamster ovary cells was performed on our behalf by
Euroﬁns Panlabs Taiwan, LTD (Taipei, Taiwan) using a standard
protocol (20,21). Brieﬂy, blonanserin or vehicle was pre-incubated
with the membranes and guanosine diphosphate (GDP, D2L: 10 mMor D3: 1 mM) inmodiﬁed HEPES buffer (pH 7.4) for 20min, and then
SPA scintillation beads were then added, and the whole was
incubated for another 60 min at 30 C. The reaction was initiated
by addition of 0.3 nM [35S]GTPgS followed by incubation for
another 15 min (D2L) or 30 min (D3). Blonanserin agonistic activity
was assessed at 10 mM, and its antagonistic activity for dopamine
(D2L: 10 mM or D3: 0.3 mM)-induced response was evaluated at
0.03 nMe10 mM. Blonanserin KB value was calculated according to
the Cheng-Prusoff equation: KB ¼ IC50 of blonanserin/[1þ (the
concentration of dopamine)/EC50 of dopamine]. EC50 values of
dopamine for D2L and D3 receptors were 610 and 10 nM,
respectively.2.5. In vivo D2 and D3 receptors occupancy in rats
In vivo D2 and D3 receptors binding experiments were per-
formed, on our behalf by Shin Nippon Biomedical Laboratories, as
previously described (9,22) with minor modiﬁcations. Rats were
orally administered test-drugs or vehicle and returned to their
home cages. Sixty minutes later, the rats were intravenously
injected with [3H]-(þ)-PHNO, a D2/D3 receptor radiotracer, at
0.3 nmol/kg. Sixty minutes after the tracer injection, the animals
were sacriﬁced by decapitation, and their brains were removed and
chilled in ice-cold saline. The striatum and cerebellar lobes 9 and 10
(L9/10) were dissected out for assessment of binding to D2 and D3
receptors, respectively. The cerebellar cortex, without cerebellar
L9/10, in the vehicle-treated rats was also dissected out and used as
reference region with low D2 and D3 receptors distribution. After
weighting, the samples were placed in scintillation vials and dis-
solved in 1.5 mL Soluene-350 (PerkinElmer, Inc.). They were next
decolorized by addition of 0.5 mL 30% H2O2 and 0.5 mL iso-
propanol. Ten milliliters of a liquid scintillation cocktail (Hionic
Fluor, PerkinElmer) was then added, and the radioactivity was
counted using a liquid scintillation analyzers (TRI-CARB 3100 TR,
PerkinElmer).
The radioactivity in each sample was ﬁrst expressed as 3H
disintegration per minute per mg of tissue (DPM/mg). Speciﬁc
binding ratio (SBR), which represents the ratio of speciﬁc to non-
displaceable radiotracer binding, was calculated as follows:
(DPM/mg in the region of interest e DPM/mg in the reference re-
gion)/DPM/mg in the reference region. Test-drugs binding inhibi-
tion for each receptor was calculated by the following equation:
binding inhibition (%) ¼ [(SBR in vehicle-treated group)(SBR in
compound-treated group)]/(SBR in vehicle-treated group)  100.2.6. Rat methamphetamine-induced locomotor hyperacitivity
model
We determined test-drugs ED50 values for inhibition of
methamphetamine-induced locomotor hyperactivity in rats, i.e.
antipsychotic-like doses. Locomotor activity was measured as
previously described (23). Brieﬂy, rats were injected with meth-
amphetamine (1 mg/kg i.p.) and then individually moved to clear
plastic cages (outer diameter: width 220 mm, depth 380 mm,
height 205 mm). The rats locomotor activity was measured for
80 min starting 10 min after methamphetamine injection using an
activity monitoring system (Supermex; Muromachi Kikai Co. Ltd.,
Tokyo, Japan). Test-drugs or vehicle was orally administered 60 min
before methamphetamine injection. Percentage inhibition of
methamphetamine-induced hyperactivity in each rat was calcu-
lated using the following formula; Percentage inhibition ¼ (AB)/
A 100, where A represents total locomotion in the vehicle-treated
group and B represents total locomotion in each animal.
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In the D2 and D3 receptors occupancy in vivo, the ED50 and its
95% conﬁdence interval was estimated by Fieller's method using
Stat PrecliniCa software package (Takumi Information Technology
Inc.). Total locomotion was compared among the groups in each
experiment by parametric Dunnett multiple comparison test using
Stat Preclinica. The ED50 value of methamphetamine-induced hy-
peractivity and its 95% conﬁdence interval for each test-drug were
estimated by the non-linear regression according to the logit model
using SAS Enterprise Guide (SAS Institute Inc.). Test-drugs D2 and
D3 receptors occupancy at effective antipsychotic doses (ED50
values for inhibition of methamphetamine-induced locomotor
hyperactivity) was estimated from occupancy doseeresponse data
by Fieller's method.
3. Results
3.1. In vitro binding assay
The in vitro binding afﬁnity of blonanserin and other atypical
antipsychotics for the human D3 receptor was determined using
membrane preparations of recombinant cells expressing the human
D3 receptor. All test-drugs inhibited the binding of [3H]-spiperone to
human D3 receptors (Table 1). Blonanserin exhibited the highest
binding afﬁnity for D3 receptors (Ki ¼ 0.277 ± 0.008 nM, Table 1)
among all tested drugs. The binding potency order was as follows:
blonanserin (Ki ¼ 0.277 ± 0.008 nM) > aripiprazole
(Ki¼3.98±0.50nM)> risperidone(Ki¼7.50±0.41nM)>olanzapine
(Ki ¼ 74.2 ± 5.02 nM).
3.2. In vitro GTPgS binding assay
Blonanserin inhibited dopamine-induced [35S]GTPgS binding
for D2L and D3 receptors with KB values of 0.0132 ± 0.0004 nM and
0.0273 ± 0.0014 nM, respectively. Blonanserin at 10 mM did not
increase [35S]GTPgS binding to the membrane preparations of hu-
man D3 or D2L receptors (data not shown).
3.3. In vivo D2 and D3 receptors occupancy in rats
In vivo D2 and D3 receptor binding experiments were performed
in two separate experiments. Sixty minutes after injection of [3H]-
(þ)-PHNO, total radioactivity in the vehicle-treated rats was
48.56 ± 2.22 and 44.39 ± 3.02 (striatum), 43.21 ± 4.33 and
42.86 ± 2.44 (cerebellum L9/10), 9.97 ± 0.33 and 9.57 ± 0.24 DPM/
mg (cerebellum without L9/10).
The occupancy of test-drugs for D2 and D3 receptors were
measured in the striatum (D2 receptor-rich region) and cerebellum
L9/10 (D3 receptor-rich region), respectively. The dopamine D3Table 1
Binding afﬁnity of atypical antipsychotics.
Compounds Binding afﬁnity for human recombinant receptor (Ki, nM)
Dopamine D2La Dopamine D3 Serotonin 5-HT2Aa
Blonanserin 0.284 ± 0.068 0.277 ± 0.008 0.640 ± 0.018
Risperidone 4.19 ± 0.25 7.50 ± 0.41 0.227 ± 0.026
Olanzapine 35.4 ± 4.3 74.2 ± 5.02 0.787 ± 0.023
Aripiprazole 0.988 ± 0.103 3.98 ± 0.50 6.30 ± 0.64
Data were expressed as mean ± SEM (n ¼ 3). The following radioligands were used:
[3H]-spiperone (0.44 nM) for D2L receptors, [3H]-spiperone (1.1 nM) for D3 receptors
and [3H]-ketanserin (0.42 nM) for 5-HT2A receptors.
a These data were previously reported (12).receptor-selective antagonist SB-277011-A (10 mg/kg p.o.) inhibi-
ted the binding of [3H]-(þ)-PHNO in the cerebellum L9/10, but not
in the striatum (Fig. 1E). All other test-drugs, i.e. blonanserin
(ED50 ¼ 0.081 mg/kg p.o.), risperidone (ED50 ¼ 0.35 mg/kg p.o.),
olanzapine (ED50 ¼ 1.55 mg/kg p.o.) and aripiprazole
(ED50 ¼ 4.99 mg/kg p.o.) inhibited the binding of [3H]-(þ)-PHNO in
the rat striatum (Fig. 1AeD and Table 2). In the cerebellum L9/10,
blonanserin (ED50 ¼ 0.28 mg/kg p.o.) and risperidone
(ED50 ¼ 3.07 mg/kg p.o.) inhibited the binding of [3H]-(þ)-PHNO
(Fig. 1A and B, Table 2). On the other hand, olanzapine and aripi-
prazole inhibited less than 50% of [3H]-(þ)-PHNO binding even at
30 mg/kg p.o. (Fig. 1C and D). As for ED50 ratio in the D3 receptor-
versus D2 receptor-rich regions, blonanserin exhibited the highest
values (0.29 fold) among the test-drugs (Table 2).
3.4. Estimation of test-drugs D2 and D3 receptors occupancy at ED50
values for inhibition of methamphetamine-induced locomotor
hyperactivity in rats
All test-drugs inhibited methamphetamine-induced locomotor
hyperactivity in rats. Oral administration of blonanserin (0.3, 1 and
3mg/kg), risperidone (1 and 3mg/kg), olanzapine (3 and 10mg/kg)
or aripiprazole (10 and 30 mg/kg) signiﬁcantly reversed
methamphetamine-induced locomotor hyperactivity in rats
(Fig. 2AeD). The ED50 values for this inhibition are shown in Table 3.
Among all test-drugs, blonanserin exhibited the lowest ED50 value
(0.66 mg/kg p.o.), which was slightly lower than that of risperidone
(0.72mg/kg p.o.), but more than 5-fold or 12-fold lower than that of
olanzapine (3.56 mg/kg p.o.) or aripiprazole (8.35 mg/kg p.o.),
respectively.
Although all test-drugs showed high D2 receptor occupancy
(blonanserin: 91.5%, risperidone: 75.9%, olanzapine: 80.9%, and ari-
piprazole: 62.0%, Table 3), only blonanserin showedhighD3 receptor
occupancy at ED50 values for inhibition of methamphetamine-
induced locomotor hyperactivity (76.8%, Table 3). The estimated D3
receptor occupancy of risperidone was relatively low (20.2%,
Table 3). The D3 receptor occupancy of olanzapine and aripiprazole
could not be estimated, since both drugs at the highest doses used in
in vivo binding assay exhibited less than 50% occupancy of this
receptor.
4. Discussion
In the present study, we found that among the evaluated drugs,
blonanserin at its antipsychotic-like dose occupies the highest
percentage (76.8%) of the D3 receptor in rats compared to risperi-
done, olanzapine or aripiprazole all of which preferably occupied
the D2 receptor (Table 3), as previous reported (6e9).
In in vitro binding assay, blonanserin, among all test-drugs, had
the most potent binding afﬁnity (Ki ¼ 0.277 nM) for human D3
receptors. The potent binding afﬁnity of blonanserin for this re-
ceptor is consistent with its Ki value (Ki¼ 0.494 nM) in the previous
paper (24). It has been reported that dopamine, the endogenous
receptor agonist, binds to D3 receptors with a 70-fold greater af-
ﬁnity than to dopamine D1 and D2 receptor subtypes (25,26).
Therefore, the potent D3 receptor binding afﬁnity of drugs may be
required to act in vivo via a mechanism that involves this receptor
due to the competition with dopamine. In addition, human PET
studies have shown that antipsychotics clinical doses are deter-
mined based on their occupancy of the D2 receptor (1). Therefore,
the overall binding afﬁnity relative to that for D2 receptors is also
important for efﬁcacy.When Ki value of blonanserin for D3 receptor
was compared to previously reported Ki value for D2L receptor
(Table 1) (12), blonanserin has a similar binding afﬁnity for both
dopamine D2L and D3 receptors in vitro. Further, our GTPgS binding
Figure 1. In vivo D2 and D3 receptor occupancy of atypical antipsychotics in rats. (A) Blonanserin, (B) risperidone, (C) olanzapine, (D) aripiprazole or (E) SB-277011-A was orally
administered 60 min before injection of [3H]-(þ)-PHNO. Sixty min after the tracer injection, inhibition of [3H]-(þ)-PHNO binding was evaluated in D2 receptor-rich region (striatum)
and D3 receptor-rich region (cerebellum L9/10). Values correspond to the mean ± S.E.M. (n ¼ 4).
Table 2
D2 and D3 receptors occupancy of antipsychotics in rats.
Compounds ED50 (95% conﬁdence limits) ED50 ratio D3 vs. D2 (fold)
D2 receptor-rich region D3 receptor-rich region
Blonanserin 0.081 mg/kg p.o. (0.068e0.097) 0.28 mg/kg p.o. (0.18e0.44) 0.29
Risperidone 0.35 mg/kg p.o. (0.24e0.51) 3.07 mg/kg p.o. (1.79e5.90) 0.11
Olanzapine 1.55 mg/kg p.o. (1.08e2.14) N.D. N.D.
Aripirazole 4.99 mg/kg p.o. (3.42e7.26) N.D. N.D.
N.D., Not determined (these compounds showed less than 50% occupancy at the highest doses).
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for dopamine D2L and D3 receptors at the similar concentration
range.
A new method for measurement of dopamine D2 and D3 re-
ceptors occupancy in rats using [3H]-(þ)-PHNO has recently been
reported (9,22). Using this method, we conﬁrmed that the dopa-
mine D3 receptor-selective antagonist SB-277011-A reverses the
binding of [3H]-PHNO in the cerebellum L9/L10, but not in the
striatum, whereas all tested antipsychotics potently reverse the
binding of [3H]-PHNO in the striatum (9,22). These results indicate
that the newly reported methods allow distinction of occupancy
between of dopamine D2 and D3 receptors.In the current study, blonanserin exhibited the highest occu-
pancy of D3 receptors in rats. The doses of test-antipsychotics were
selected based on each drug efﬁcacy inmethamphetamine-induced
locomotor hyperactivity, which is one of the most commonly used
behavioral tasks for assessing drugs antipsychotic-like effects in
rodents. At its antipsychotic-like dose (ED50 ¼ 0.66 mg/kg p.o.),
blonanserin showed the highest occupancy of D3 receptors among
all test-drugs. On the other hand, risperidone, olanzapine and ari-
piprazole at their antipsychotic-like doses showed weak or negli-
gible occupancy of this receptor. These ﬁndings indicate that
blonanserin has a unique proﬁle characterized by potent inhibition
of the D3 receptor in vivo.
Figure 2. Effects of antipsychotics on methamphetamine-induced locomotor hyperactivity in rats. (A) Blonanserin, (B) risperidone, (C) olanzapine or (D) aripiprazole was orally
administered 60 min before injection of methamphtemine (1 mg/kg i.p.). Locomotor activity was measured for 80 min starting 10 min after methamphetamine injection. Values
correspond to the mean ± S.E.M. (n ¼ 6). *P < 0.05, **P < 0.01 vs. vehicle/methamphetamine-treated groups (Dunnett test).
Table 3
Estimated D2 and D3 receptors occupancy at effective antipsychotic doses in rats.
Compounds Effective antipsychotic dosesa
(95% conﬁdence limits)
Estimated D2 and D3 receptor
occupancy at effective
antipsychotic doses
Dopamine D2 Dopamine D3
Blonanserin 0.66 mg/kg p.o. (0.49e0.89) 91.5% 76.8%
Risperidone 0.72 mg/kg p.o. (0.52e0.99) 75.9% 20.2%
Olanzapine 3.56 mg/kg p.o. (2.65e4.77) 80.9% N.D.
Aripiprazole 8.35 mg/kg p.o. (5.36e13.03) 62.0% N.D.
N.D., Not determined (these compounds showed less than 50% occupancy at the
highest doses).
a Effective antipsychotic doses were deﬁned as ED50 values for inhibition of
methamphetamine-induced locomotor hyperactivity in rats (n ¼ 6).
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in vitro and in vivo binding for dopamine D3 receptors (6,7,9).
Although the reasons for these discrepancies are unknown, most
typical and atypical antipsychotics show no or very low in vivo D3
receptor occupancy at their antipsychotic doses in rats, despite their
considerable binding afﬁnity for D3 receptors in vitro. Furthermore,
PET studies have conﬁrmed that current antipsychotics, such as
risperidone, olanzapine and clozapine, donot occupyD3 receptors in
patients with schizophrenia (10,11). Therefore, the use of in vivo D3
receptor binding assay in the rat brain may be appropriate for
evaluation of D3 receptor binding afﬁnity capacity in the human
brain. In fact, recent studies have shown that cariprazine, a D2/D3
receptor partial agonist, not only occupies rat D2 and D3 receptors
in vivo (8), but also shows high occupancy for both D2 and D3receptors in patients with schizophrenia (27). However, a baboon
PET study demonstrated that clozapine and haloperidol bind to
dopamine D3 receptors, which contrasts results obtained with ro-
dents and human PET studies (28). This discrepancymight be due to
different experimental methodologies, such as anesthesia, mea-
surement duration, and data analysis. Since we found that among
testeddrugsblonanserin shows thehighestoccupancy fordopamine
D3 receptors at its antipsychotic-like dose, it is worth evaluating this
drug occupancy of dopamine D3 receptors at its clinical dose.
Several animal studies have suggested that the antagonism of D3
receptor is beneﬁcial for cognitive deﬁcits, negative symptoms and
extrapyramidal symptoms (3e5). As our GTPgS-binding assay
showed that blonanserin acts as a potent full antagonist for dopa-
mine D3 receptors, D3 receptor antagonism of blonanserin might
contribute, at least in part, to its efﬁcacy and safety proﬁle. A recent
animal study has demonstrated that the beneﬁcial effects of blo-
nanserin on prefrontal dopamine transmission and visual-
recognition memory are reversed by co-treatment with a dopa-
mine D3 receptor agonist 7-OH-DPAT in mice, which indicates that
blonanserin shows cognitive efﬁcacy via D3 receptor antagonism
(29). Interestingly, open-labeled clinical studies have shown that
blonanserin improves verbal ﬂuency and executive function, both
of which are related to prefrontal cortex function, in patients with
schizophrenia (30,31).
In conclusion, we have shown in this study that blonanserin, but
not other tested antipsychotics, extensively occupies D3 receptors
in vivo in rats. Future translational studies are needed to clarify the
role of D3 receptors in the efﬁcacy and safety proﬁle of blonanserin
in animals and humans.
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